SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is generating intense buzz ahead of its highly anticipated BlueBird 6 satellite launch, which is viewed as a pivotal moment for its space-based cellular network deployment. The community is sharply divided, with fervent bulls anticipating substantial gains post-launch, while bears warn of an overvalued stock and a potential "sell the news" event. This dichotomy is fueling significant conversation and market volatility around the company's future in satellite communications.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending due to widespread anticipation surrounding the outcome of a recent FDA meeting concerning its lead drug, Sonelokimab, for Hidradenitis Suppurativa. The community largely expects a positive regulatory update, which many believe would significantly de-risk the asset. This has intensified discussions about a potential acquisition by a major pharmaceutical player, fueled by reported prior interest and recent executive share conversions interpreted by some as preparatory for a substantial transaction.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending amid strong community buzz surrounding its upcoming merger with Infleqtion, a quantum technology leader. Investors are highlighting Infleqtion's established partnerships with defense and aerospace entities, along with its commercially viable quantum sensing and timing solutions, which many believe are significantly undervalued compared to sector peers. The sentiment suggests anticipation for substantial institutional investment and accelerated growth once the ticker changes post-merger.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending due to anticipation surrounding its showcase of commercial quantum computing solutions and real-world applications at an upcoming major tech event, fueling speculation about its "quantum supremacy" in optimization. The community is actively debating its potential as a generational technology, drawing comparisons to early AI, while skeptics point to its current low revenue, cash burn, and perceived overvaluation amidst allegations of manipulated "pump and dump" cycles.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is experiencing extreme volatility following its recent IPO, igniting intense community debate. Bulls highlight its low float and aerospace sector exposure as potential catalysts for a massive squeeze, while skeptics label it a pump-and-dump, raising concerns about its valuation, pre-revenue status, and the qualifications of its R&D team. The stock's dramatic price swings and unusually high short borrow fees are central to the ongoing, heated discussion.

TOSHI

TOSHI is a trending topic, with its community deeply engaged in discussions around its role as the "Face of Base" blockchain following recent listings on major exchanges and a Coinbase One collaboration. Despite recent market volatility, the "blue cat" faithful are actively accumulating, anticipating future growth and potential listings on platforms like Robinhood or Binance, highlighting strong long-term conviction.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is generating buzz following a series of strategic teaming agreements that position its specialized thin-film solar technology for critical applications across the growing space, aerospace, and defense sectors. The community is actively debating the stock's high volatility and long-term potential for significant contracts, with discussions weighing its innovative solar solutions for lunar missions and drone powering against concerns about its historical dilution.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending with intense anticipation surrounding a pivotal FDA decision for its drug Narsoplimab (Yartemlea) by December 26th, targeting a life-threatening condition without an approved treatment. This binary event is bolstered by the recent closing of a significant deal with Novo Nordisk, bringing in substantial upfront cash and potential future milestones, along with a $100 million share repurchase program, fueling community expectations for a transformative approval and a notable short squeeze.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending after receiving federal regulatory approval to restart its Las Flores Pipeline System, a move perceived as a crucial step toward reactivating its California offshore oil assets under federal oversight. This development has spurred significant community discussion, with many investors anticipating substantial upside and a potential short squeeze, while others remain cautious due to the company's financial concerns and the likelihood of continued state-level legal and permitting challenges.

ProShares Trust - ProShares Ultra Bitcoin ETF

ProShares Ultra Bitcoin ETF

ProShares Ultra Bitcoin ETF ($BITU) recently saw a notable price drop, sparking immediate concern and confusion among investors. The community quickly identified this as a significant dividend or distribution payment, shifting conversations to its impact and the broader outlook for this leveraged Bitcoin ETF amid ongoing cryptocurrency market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +4.74% and +2.80%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

Bioventus (BVS) delivered earnings and revenue surprises of -4.55% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates

Indivior (INDV) delivered earnings and revenue surprises of +96.15% and +22.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Shares of CASI Pharmaceuticals, Inc. (CASI) traded 5% higher on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6899273834937655">announced</a> that it has received a buyout proposal valuing the company’s operations in China at $20 million.The proposal, dated April 2, was put forth by company CEO Wei-Wu He and covers the company’s entire business operations in China and all license-in, distribution, and related rights in Asia, excluding Japan, related to certain pipeline products.CASI said the proposal updates the preliminary non-binding proposal letter submitted by He to the company on June 21, 2024.The company said that its special committee of the board of directors will evaluate the proposed transaction. However, no decisions have been made regarding the proposal letter or any alternative strategic option the company may pursue. &nbsp;The company added that there is no assurance that any definitive agreement relating to the proposal letter will be entered between the company and its CEO.On Stocktwits, retail sentiment about CASI Pharmaceuticals dipped slightly within the ‘extremely bullish’ territory (94/100), accompanied by a slight drop in message volume over the past 24 hours.<figure class="image"><img style="aspect-ratio:654/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_1_58_58_PM_png_20cfaa728f.webp" alt="CASI's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 3, 2025 | Source: Stocktwits" width="654" height="149"><figcaption>CASI's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> Late last month, CASI Pharma reported full-year 2024 revenue of $28.5 million, a decrease of 16% compared to 2023. The company noted that it was impacted by intensified competition and increased pricing pressure during the year.Net loss for the year came in at $39.3 million, higher than the $26.3 million reported in 2023.The company added that it had cash and cash equivalents of $13.5 million as of the end of 2024, less than the $29.1 million as of 2023-end.<a href="https://stocktwits.com/symbol/CASI">CASI shares</a> are down by over 25% this year and over 30% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gm-marks-marginal-sales-growth-in-china-in-q1/chf7IpJRbeZ">GM Marks Marginal Sales Growth In China In Q1: But Retail Continues To Stay Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

The company said that its special committee of the board of directors will evaluate the proposed transaction.

Equity

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.

CASI
CASI Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CASI News

CASICASI Pharmaceuticals Inc